Long Term Methotrexate Therapy Beneficial for Juvenile Localized Scleroderma PDF Print E-mail
Wednesday, 20 February 2013 00:03
Researchers in Italy evaluated 65 patients with Juvenile Localized Scleroderma (JLS; or morphea) previously enrolled in a double blind, randomized control trial and treated for the first 3 months with oral methotrexate (MTX; 15 mg/m2 weekly) and prednisone (1 mg/kg daily, maximum 50 mg). Clinical evaluation, infrared thermography and computerized skin scores were used to evaluate lesions.

Patients were defined as responders if they satisfied criteria including no new lesions, skin score rate less than 1 and a decrease in lesion temperature by at least 10% compared with baseline. Maintaining responder status after stopping treatment for at least 6 months was classified as clinical remission (CR), and response maintained while taking MTX for at least 6 months defined CR on medication (CRM).

Fifty-eight patients (mean age, 9.4 years; 72.4% female) were followed up during a mean of 40.3 months; seven were lost to follow-up. Forty-eight patients were responders at the last follow-up, while 10 patients relapsed within 24 months of MTX initiation. Responders were evaluated every 3 to 4 months during a mean of 43 months. Thirty-five responders received MTX for a mean of 27.5 months and then maintained CR for 25.6 months or longer without MTX. Thirteen other responders were in CRM. Twenty-eight patients experienced mild MTX-related side effects, including nausea and headache, but maintained treatment.

Researchers cited difficulty in comparing data to previous studies because objective measures such as infrared thermography and computerized skin score were unavailable.

“Long-term maintenance MTX treatment is beneficial for localized scleroderma (morphea) in young patients and is generally well tolerated with rare occurrence of significant adverse events,” the researchers concluded. “We recommend an initial 3 months of combined MTX-corticosteroid therapy and MTX treatment duration of at least 24 months to ensure a prolonged and sustained disease remission for the majority of the patients.”

Source: Healio Dermatology (2013), "Long-term methotrexate therapy effectively treated juvenile localized scleroderma"; Original article can be viewed here.

 
More articles :

» Important Information On Flaxseed And Flaxseed Oil

Flaxseed, called linseed in some countries, is a good source of dietary fiber, , and . Each of these components may contribute to the health effects of eating flaxseed, but flaxseed oil contains no fiber and very little lignan. In addition to its...

» Caribbean Autoimmune Diseases 2011 Summit Highlights

On Sunday October 2nd 2011, the Caribbean Investor Network hosted its Caribbean Autoimmune Diseases Summit at the Ballroom of the Hilton Hotel and Conference Centre.The Summit delivered an array of excellent presentations ranging from the common...

» Scleroderma Herbal Treatments

is a connective tissue disease. It causes the skin and internal organs to become hard and tight. This hardening can make it difficult for the sufferer to walk or move and can cause organs to fail. According to the Scleroderma Foundation, in the...

» PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers

Systemic sclerosis- (SSc-) related vasculopathy, as manifested by Raynaud’s Phenomenon (RP) and digital ulcers (DUs), is associated with significant impairment of the quality of life and morbidity. The current vasoactive approach for SSc-RP,...

» New Classification Criteria Developed For Scleroderma

The 2013 Classification Criteria for Systemic Sclerosis have been developed and validated by the and and should allow patients to be identified and treated earlier, according to the professional bodies.Published in Arthritis and Rheumatism, the...

» New Promising Therapy Against Systemic Sclerosis

There is a new path to defeat systemic sclerosis, also called because of the hardening of the skin of the patients (from Greek skleros, "hard", and derma, "skin"). This path involves the B-cell of the immune system, so far only considered "innocent...